The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?
S. M. Domchek
No relevant relationships to disclose
T. Friebel
No relevant relationships to disclose
S. L. Neuhausen
No relevant relationships to disclose
H. T. Lynch
No relevant relationships to disclose
C. F. Singer
No relevant relationships to disclose
R. A. Eeles
No relevant relationships to disclose
C. Isaacs
No relevant relationships to disclose
N. M. Tung
No relevant relationships to disclose
P. A. Ganz
No relevant relationships to disclose
F. J. Couch
No relevant relationships to disclose
J. N. Weitzel
No relevant relationships to disclose
O. I. Olopade
No relevant relationships to disclose
W. S. Rubinstein
No relevant relationships to disclose
G. E. Tomlinson
No relevant relationships to disclose
G. C. Pichert
No relevant relationships to disclose
M. B. Daly
No relevant relationships to disclose
E. T. Matloff
No relevant relationships to disclose
D. G. Evans
No relevant relationships to disclose
J. E. Garber
No relevant relationships to disclose
T. R. Rebbeck
No relevant relationships to disclose